Pessimism Depletes Pocketbooks<br />By Rev Shark<br />RealMoney.com Contributor<br />8/24/2009 8:44 AM EDT <br /><br /><br />"Every now and then, go away, and have a little relaxation. To remain constantly at work will diminish your judgment. Go some distance away, because work will be in perspective, and a lack of harmony is more readily seen." <br /><br />-- Leonardo da Vinci <br />It is good to be back in the saddle after taking a little break. My last note on Monday as the market was pulling back sharply was that I expected that the market would continue to hold up fairly well and was unlikely to suddenly collapse. I did not expect that it would hold up as well as it did and go straight up four days in a row and make a very strong push to a new high on Friday. <br /><br />There is no question about the extremely strong price action. There are very persistent bids under this market as the players continue to look for ways to add some long exposure on any weakness. <br /><br />What is supporting this market more than anything is the skepticism that still exists about the overall economy in many quarters. Few folks are as optimistic about the pace of an optimistic recovery as the market seems to be. However the market is staying stubbornly strong, and pessimism isn't making anyone any money these days. If you haven't been extremely positive about the market for months, you have been on the wrong side of the trade. <br /><br />So now what? My approach is that we have to continue to respect the price action above all else. It is extremely easy to argue against this strong market on a fundamental basis, but the market isn't listening. It doesn't matter how logical and insightful and brilliant your analysis might be. The market is acting well, and that needs to be respected above all else. <br /><br />Even though this market has been extremely strong, the irony is that it has not been easy for many bulls, and that is what is keeping it so strong. We simply have not had pullbacks or basing activity to set up easy entry points. If you want to be in, you've had to chase momentum, and that is not the preferred approach of many. <br /><br />We have some minor follow-through this morning and not much news on the wires. After the strength of the last four days, it would be reasonable to expect some consolidation at this point, but what has made this market so tricky is how quickly buyers are to jump in on the slightest pause. <br /><br />Expecting this market to keep on trending up may be tough in theory, but until conditions change, that is what we need to do. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: NPD +16.1% (also announces resignation of Co-Chief Executive Officer, effective August 20, 2009), SNP +4.8% (light volume)... Select financial stocks showing continued strength: AIG +5.3%, RBS +4.5%, C +4.3%, AIB +4.0%, ING +4.0%, MBI +3.3%, RF +3.2%, FITB +2.4%, BBV +2.4% (BBVA Compass acquires banking operations of Guaranty Bank), ABB +2.1%, BAC +1.8%, AZ +1.7%, CS +1.3%, STI +1.3%... Select metals/mining names trading higher: RTP +3.0% (Chinalco open to talks with Rio Tinto - WSJ), MT +2.3%, BHP +2.2%, GOLD +1.8%, SLV +1.4%, AUY +1.3%... Select solar names seeing early strength: YGE +3.6%, FSLR +2.8%, STP +2.6%, CSIQ +2.1%... Select coal related names ticking higher with FT reporting that coal prices have jumped as a drop in Chinese domestic output forces the country to import: ACI +3.1%, BTU +1.1%... Other news: ARIA +9.4% (announces that the Court of Appeals granted their petition for rehearing En Banc in the Lilly NF-kB patent lawsuit), MELA +7.3% (mentioned positively in Barron's), CTIC +6.5% (FDA has accepted and has filed for review the co's New Drug Application for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma), BCRX +6.4% (still checking), CRESY +5.6% (still checking), LVS +3.0% (checking for anything specific)... Analyst comments: DFS +10.6% (upgraded to Overweight at Barclays), SBGI +8.4% (upgraded to Buy at Benchmark), AMD +5.4% (upgraded to Buy at Citigroup), HIBB +2.7% (upgraded to Overweight at JPMorgan), AXP +2.3% (upgraded to Overweight at Barclays), COF +2.0% (upgraded to Overweight at Barclays), CAKE +1.9% (upgraded to Neutral at Piper Jaffray), BRCD +1.8% (upgraded to Buy at Argus based on valuation). <br /><br />Allapoole avanevad:<br /><br />General news: RRR -11.8% (reports distribution of Ripplewood Holdings' share ownership to its limited partners), VRX -7.6% (announces that Phase IIa Retigabine study for PHN does not meet pre-specified primary efficacy endpoint), SHPGY -1.3% (still checking)... Analyst comments: SWHC -2.7% (downgraded to Neutral at Wedbush Morgan), CREE -2.5% (downgraded to Hold at Kaufman), KSU -2.1% (light volume, downgraded to Neutral at UBS), TOL -1.6% (downgraded to Hold at Citigroup), OFC -1.1% (downgraded to Underperform from Market Perform at Wells Fargo).